Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.

Fiche publication

Date publication

février 2022

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr FOUCHER Pascal , Dr MENNECIER Bertrand , Dr DORY Anne

Tous les auteurs :
Slimano F, Le Bozec A, Cransac A, Foucher P, Lesauvage F, Delclaux B, Dory A, Mennecier B, Bertrand B, Gubeno-Dumon MC, Dukic S, Mongaret C, Bouché O, Hettler D, Boulin M, Dewolf M, Kanagaratnam L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35263663

Résumé

Pemetrexed is associated with hematological toxicity. Drug-drug interactions (DDIs) between methotrexate and proton pump inhibitors (PPIs) induce a higher risk of hematological toxicity due to the inhibition of methotrexate excretion by PPIs. As pemetrexed and methotrexate are both excreted by human organic anion transporter 3 (hOAT3), this study investigates the hypothetical DDI between pemetrexed and PPIs in lung cancer patients. The primary objective was the occurrence of severe (grade ≥ 3) hematological toxicity. The secondary objectives were to describe the type of hematological toxicity and associated clinical consequences (NCT03537833).